CooperCompanies stock falls sharply as Q3 2026 guidance cut weighs on outlook
Published on 09/15/2026 at 12:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CooperCompanies stock (ISIN US21664P1039) closed at USD 54.17 on the Nasdaq on September 14, 2026, down USD 9.31 or 14.6 percent from the prior session after investors reacted to weaker Q3 2026 results and a cut to full-year guidance. As Morningstar reported on September 14, 2026, that move pushed the shares to a 52-week low around USD 54.17 and erased more than USD 1.7 billion of market capitalization in a single day.Morningstar
Q3 2026 results and guidance cut pressure the stock
According to TradingKey’s Q3 FY2026 earnings summary published on September 14, 2026, CooperCompanies’ fiscal Q3 2026 revenue rose 1 percent to USD 1.066 billion, while GAAP diluted EPS jumped to USD 2.24 from USD 0.49 a year earlier, largely thanks to a USD 307.2 million tax benefit in the United Kingdom.TradingKey Non-GAAP diluted EPS increased 4 percent in the quarter to USD 1.15, modestly ahead of analyst expectations, but revenue still came in below Wall Street’s USD 1.10 billion consensus, a shortfall of roughly USD 30 million that set the tone for the market reaction.Yahoo Finance
Segment performance was mixed. TradingKey notes that CooperVision revenue was flat year on year in Q3 2026 as U.S. channel inventory reductions weighed on demand, while CooperSurgical grew 2 percent on a reported basis and 3 percent organically in the same period.TradingKey A separate shareholder investigation announcement from SueWallSt on September 14, 2026 highlighted that quarterly revenue of about USD 1.07 billion fell short of analyst expectations by roughly USD 30 million and pointed out that CooperVision’s reported revenue of USD 717 million was flat against the prior year, underscoring the pressure on the core contact lens business.GuruFocus
Full-year 2026 guidance lowered on weaker demand
Beyond the backward-looking figures, the more damaging blow for CooperCompanies stock came from a weaker outlook. As Yahoo Finance reported on September 14, 2026, the company cut its fiscal 2026 profit and revenue forecasts, now guiding to adjusted earnings of USD 4.51–4.55 per share compared with its previous forecast of USD 4.58–4.66, and revenue of USD 4.23–4.25 billion versus an earlier range of USD 4.29–4.32 billion.Yahoo Finance TradingKey’s earnings review mirrors this updated guidance, citing fiscal 2026 revenue expectations of USD 4.229–4.252 billion and non-GAAP EPS of USD 4.51–4.55, a step down from the initial revenue target of roughly USD 4.30–4.34 billion at the start of the year.TradingKey
The weaker outlook is closely tied to softer trends in the contact lens franchise. Yahoo Finance notes that CooperCompanies now expects CooperVision organic growth of only 1–2 percent for fiscal 2026, with fourth-quarter CooperVision organic growth projected in a range from negative 2 percent to zero.Yahoo Finance In addition, Morningstar’s summary of management commentary on September 9, 2026 highlighted that legacy hydrogels were down double digits across the board and that results in the Americas reflected U.S. channel inventory reductions, reinforcing the narrative that demand is weaker than previously assumed.Morningstar
Market reaction, valuation context and analyst views
The market’s response to these developments has been severe. Morningstar reports that CooperCompanies shares fell 14.6 percent on September 10, 2026, closing at USD 54.17 and marking a 52-week low as investors digested the guidance cut and commentary about U.S. channel inventory destocking.Morningstar The stock’s drop left it several dollars above a recent 52-week low near USD 51.01 and well below a 52-week high close to USD 89.83, underperforming the Nasdaq Composite index, which declined only about 0.6 percent on the same day.Ad-hoc-news
From a longer-term perspective, Zacks noted on September 14, 2026 that The Cooper Companies carries a Zacks Rank 5 (Strong Sell) and that its shares have declined 29.2 percent over the past month compared with a 0.8 percent decrease for the Zacks S&P 500 composite, while over the past three months CooperCompanies is down 18.2 percent against a 3.9 percent gain for the broader index.Zacks In a sector comparison piece, Yahoo Finance similarly pointed out that CooperCompanies delivered the weakest performance against analyst estimates and the weakest full-year guidance update among a group of medical devices and supplies peers, and that the stock trades around USD 53.93, down about 15 percent since the results.Yahoo Finance
Analyst sentiment is not uniformly negative, however. A TipRanks-sourced report carried by The Globe and Mail on September 14, 2026 states that Stifel Nicolaus has maintained a Buy rating on Cooper Co with a price target of USD 70.00, while Mizuho Securities also reiterated a Buy in a report issued on September 11, 2026; in contrast, William Blair downgraded the stock to Hold.The Globe and Mail Ad-hoc-news cites MarketBeat data indicating that analysts currently expect CooperCompanies to post about USD 4.53 in earnings per share for the full fiscal year 2026, essentially in line with the updated company guidance and framing the debate around whether the recent sell-off has gone too far.Ad-hoc-news
Legal investigations and key risks for investors
The sharp share price move and guidance cut have also attracted legal scrutiny. A press release distributed via GuruFocus on September 14, 2026 reports that SueWallSt has launched a shareholder investigation examining whether the financial information CooperCompanies presented to investors was consistent with figures carried in its quarterly reports filed with the U.S. Securities and Exchange Commission, focusing particularly on the Q3 2026 revenue miss of around USD 30 million versus consensus and the flat performance of the CooperVision segment.GuruFocus Separately, Rosen Law Firm announced on September 14, 2026 that it is investigating potential securities claims on behalf of shareholders, citing a September 10, 2026 article from The Motley Fool that attributed the roughly 14.6 percent share price decline to weak guidance in the earnings report and the company’s decision not to sell its CooperSurgical unit.Business Wire
For investors, these investigations add another layer of uncertainty on top of the operational challenges in the contact lens business. The combination of lowered revenue and EPS guidance, softer organic growth expectations at CooperVision, and potential legal proceedings means that near-term risk is elevated even after the share price decline. At the same time, updated guidance still implies fiscal 2026 non-GAAP EPS in the mid-USD 4 range and low single-digit revenue growth, so the key question is whether management can stabilize U.S. inventory dynamics and reignite demand without further cuts to its outlook.
Stock trades near recent lows on the Nasdaq
As of the close on September 14, 2026, CooperCompanies stock traded at USD 54.17 on the Nasdaq, marking a decline of 14.6 percent on the day and leaving the shares near the bottom of their 52-week range between roughly USD 51.01 and USD 89.83. That price implies a market capitalization in the mid-single-digit billions of USD based on Morningstar’s estimate that more than USD 1.7 billion in value was wiped out by the one-day drop.Morningstar With the shares now trading more than 30 percent below their 52-week high, the balance between risk from weaker guidance and potential recovery if inventory and demand normalize has become the central consideration for market participants watching CooperCompanies stock.
CooperCompanies stock at a glance
- Company: CooperCompanies Inc.
- ISIN: US21664P1039
- Ticker: COO
- Trading venue: Nasdaq
- Price (as of September 14, 2026): 54.17 USD
- Market capitalization: mid-single-digit billions USD (as of September 14, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
